The research team, led by Lianshuai Zheng and colleagues, recruited 51 healthy pregnant women at 6 to 8 weeks of gestation, confirming early pregnancy through ultrasound visualization of the fetal heart and embryonic bud. Participants were followed prospectively throughout their pregnancies, with pregnancy complications, delivery outcomes, and neonatal health assessed at day 42 after birth. To ensure that the micronutrient data reflected healthy physiology rather than disease-related distortions, the final analysis was restricted to 43 women who completed all assessments and experienced uncomplicated pregnancies with favorable outcomes for both mother and child.

What sets this study apart from much of the existing literature is its longitudinal design combined with high-resolution analytical chemistry. Whole-blood trace elements were quantified using inductively coupled plasma mass spectrometry, or ICP-MS, a technique capable of detecting metals and metalloids at extremely low concentrations with high accuracy. Serum vitamins, meanwhile, were measured with ultra-high-performance liquid chromatography coupled to tandem mass spectrometry, known as UHPLC-MS/MS, which allows precise separation and quantification of individual vitamin species in complex biological matrices. Blood samples were collected at three defined time points: the first trimester at an average of 12.3 weeks of gestation, the second trimester at 25.6 weeks, and the third trimester at 32.7 weeks.

The results revealed a striking choreography of rising and falling concentrations. Copper, calcium, and vitamin D all peaked during the second trimester before declining thereafter. This pattern is physiologically plausible: copper plays a central role in fetal development and maternal iron metabolism, calcium demand surges as fetal skeletal mineralization accelerates, and vitamin D status is closely tied to calcium homeostasis. The mid-pregnancy peak in these three analytes suggests a coordinated biological response to the heightened demands of the second trimester, when fetal growth is rapid and placental transfer of minerals intensifies.

In contrast, iron, zinc, magnesium, and lead reached their lowest concentrations, or nadir, during the second trimester. The dip in iron is consistent with the well-documented hemodilution of pregnancy, in which plasma volume expands faster than red cell mass, effectively diluting circulating iron even as total body iron may be conserved. Zinc and magnesium follow similar trajectories, likely reflecting the same dilutional effect combined with active fetal uptake. The parallel decline in lead is noteworthy, because it suggests that maternal blood lead concentrations may fall as pregnancy progresses, possibly through redistribution into maternal tissues and the fetal compartment, though the study was not designed to test mechanisms directly.

Not every micronutrient followed a peak-and-valley pattern. Manganese and vitamins E and K increased progressively throughout gestation, rising steadily from the first trimester through the third. Vitamin E, a lipid-soluble antioxidant, is known to travel with lipids in the bloodstream, and lipid concentrations naturally rise in pregnancy, which may partly explain the upward trend. Vitamin K is essential for blood coagulation, and the hypercoagulable state of pregnancy, which prepares the body for delivery, could drive increased demand and circulating levels. Manganese serves as a cofactor for numerous enzymes involved in metabolism and antioxidant defense, and its gradual accumulation may reflect both dietary intake and fetal developmental needs.

The B vitamins told a different story. Several members of this water-soluble family showed an overall downward trend across gestation, a pattern that may reflect increasing utilization by the fetus and placenta as well as the expanding maternal blood volume. Vitamin B12, however, remained relatively stable throughout pregnancy, standing out as an exception to the general decline. This stability is clinically relevant because B12 deficiency during pregnancy has been associated with adverse neurodevelopmental outcomes, and a stable baseline suggests that maternal stores or intake were sufficient to maintain circulating levels in this healthy cohort.

The authors emphasize that these findings demonstrate clear trimester-specific changes in maternal micronutrient levels during healthy pregnancy, a point with direct clinical implications. Many laboratories currently interpret micronutrient results in pregnant women using reference intervals derived from non-pregnant populations or from pooled data that do not distinguish between trimesters. If copper, calcium, and vitamin D naturally peak in mid-pregnancy while iron, zinc, and magnesium naturally dip, then applying a single static reference range could misclassify healthy women as deficient or excessive at particular stages of gestation. Trimester-specific reference intervals would allow clinicians to distinguish physiological adaptation from genuine deficiency or toxicity with far greater accuracy.

The regional dimension is equally important. Micronutrient status is shaped by local diet, soil and water composition, supplementation practices, and environmental exposures, all of which vary considerably across geographic areas. Lianyungang, as a coastal city with its own dietary and environmental profile, may not be representative of other regions of China or of other countries. The study’s authors therefore frame their data as preliminary evidence to inform the establishment of region-specific and trimester-specific reference intervals and deficiency thresholds for micronutrients in healthy pregnant women, rather than as universal standards.

Several caveats temper the conclusions. The sample size of 43 women in the final analysis is relatively small, which limits the statistical power to detect subtle changes and to stratify results by factors such as maternal age, parity, diet, or supplementation habits. The cohort was restricted to healthy women with uncomplicated pregnancies, so the trajectories observed here may differ in women with gestational diabetes, hypertensive disorders, anemia, or other complications. Nevertheless, the longitudinal design, the use of state-of-the-art analytical methods, and the careful confirmation of favorable maternal and neonatal outcomes lend credibility to the observed patterns. As the authors note, these longitudinal data provide a foundation upon which larger, multi-center studies can build to refine micronutrient reference standards for pregnancy, ultimately supporting more precise nutritional monitoring and care for expectant mothers worldwide.

Subject of Research: Trimester-specific fluctuations of maternal micronutrients during healthy pregnancy

Article Title: Fluctuations of micronutrients during pregnancy in Lianyungang, Jiangsu, China: A prospective longitudinal cohort study

Article References: Zheng, L., Xu, X., Rong, X., Luo, J., Chen, G., & Zhao, C. (2026). Fluctuations of micronutrients during pregnancy in Lianyungang, Jiangsu, China: A prospective longitudinal cohort study. PLOS One, 21(10), e0360813. https://doi.org/10.1371/journal.pone.0360813

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360813

Keywords: pregnancy, micronutrients, trace elements, vitamins, longitudinal cohort study, ICP-MS, UHPLC-MS/MS, trimester-specific reference intervals, maternal health, fetal development, PLOS One, Lianyungang

The meninges consist of three layers—the pia mater hugging the brain surface, the arachnoid mater above it, and the dura mater outermost. Together they anchor the brain to the skull, carry its blood supply, house immune defences, and provide the channels through which cerebrospinal fluid flows. Despite their clinical importance, no one had ever produced a single-cell atlas of the human meninges during development. That gap mattered, because tumours are known to hijack developmental programs, and identifying a tumour’s cell of origin often requires comparing it against the normal cell types present during organ formation.

To close that gap, the researchers collected meningeal tissue from 16 samples spanning postconceptional weeks 5 through 13, obtained from elective abortions with informed consent under approved ethical protocols. Using droplet-based single-cell RNA sequencing, they profiled 156,726 high-quality cells, which they organised into 245 clusters annotated across four hierarchical levels: 115 cell types, 105 subclasses, 45 classes and 8 superclasses. Fibroblasts marked by the transcription factor FOXC1 made up roughly half the dataset, alongside PECAM1-positive endothelial cells, ABCC9-positive perivascular cells, PTPRC-positive immune cells and even anucleated erythropoietic cells. Interacting neural, neural crest and choroid plexus epithelial cells were also captured, giving the atlas an unusually complete view of the brain’s outer environment.

Crucially, the team paired the sequencing with spatial transcriptomics using the Xenium platform, cryosectioning entire embryonic heads at weeks 6 and 9.5 so that the meninges remained anatomically intact. A custom probe panel targeting 389 genes, chosen from the sequencing data, allowed them to locate each cell type in situ. At week 6 they identified the primary meninx, the earliest meningeal structure described in the literature, a thin fibroblast sheet wrapping the entire brain together with FOXQ1-positive endothelial cells. By week 9.5, the spatial data revealed a remarkably complete stack of tissue layers, from the ventricular zone of the developing cortex up through Cajal–Retzius cells, meningeal fibroblasts, the future skull, periosteum and skin.

One of the atlas’s most consequential findings concerns how the three meningeal layers form. Rather than branching off from distinct precursor lineages the way blood cells do in haematopoiesis, the pia, arachnoid and dura emerged as a continuum of cell states. Layer-specific markers—LAMC3 for pia, SLC22A6 for arachnoid and COL8A1 for dura—showed smooth gene expression gradients at every age examined, and maturation scores built from adult layer-enriched genes revealed that all three layers mature concurrently, their adult gene programs already active in the first trimester and steadily increasing through week 13. Cycling cells were present in every layer, further supporting a model of parallel, gradual refinement rather than branched lineage commitment.

Within the dura, the spatial data exposed an unexpected subdivision. Beyond the thick outer dura, which expressed MSX2 and blended into osteogenic skull and periosteal tissues, the researchers found a distinct inner dura: a single sheet of cells apposed directly onto the arachnoid, marked by SLC47A1 and, surprisingly, the epithelial marker CDH1. This inner layer expressed a full complement of tight-junction genes—Occludin, several Claudins, junctional adhesion molecules and their intracellular scaffolds—plus adherens junction components and even tricellular junction proteins. In other words, the inner dura looks like a second barrier layer, histologically resembling arachnoid barrier cells rather than ordinary dura. Because the same CDH1-positive inner dura appears in adult human and mouse meninges, the team proposes that the complete meningeal barrier may be built from two cell sheets—the arachnoid barrier and the inner dura—and suggests renaming it the arachnoid–dura barrier.

The atlas also delivered surprises well beyond the dura. The fetal meninges harboured 19 immune cell types as early as week 5, including macrophages tiled sparsely across the primary meninx, microglia confined to the brain side of the leptomeningeal boundary, and—remarkably—B-lineage cells. CD34-positive, IL7R-positive, CD19-low early lymphoid progenitors appeared in the meninges at week 5, a full week earlier than such cells had been reported in fetal liver, and matured through pre-pro, pro, pre and immature B cell stages by weeks 8 to 13. This positions the meninges as an unexpected site of early human B cell differentiation. The vascular analysis was equally revealing: venous endothelial cells expressing the lymphatic transcription factor PROX1 suggested that subarachnoid lymphangiogenesis may begin in early fetal life, whereas in mice meningeal lymphatics develop only after birth.

The pivotal question, however, was what all this says about meningiomas. The team reanalysed published single-cell and bulk RNA sequencing data from human meningiomas and generated new Xenium spatial data from seven tumours, including one grade I and six grade III tumours. Using latent Dirichlet allocation topic modelling—a computational method that identifies co-expressed gene modules corresponding to cell identities—they defined 35 topics from the fetal fibroblast data, including topics for pia, arachnoid, inner dura, outer dura and a barrier topic shared between arachnoid and inner dura cells. When these topics were transferred to the tumour data, the result was unambiguous: pia and arachnoid topics were nearly absent, while inner dura, dura and barrier topics dominated. Tumour cells expressed CDH1 and SLC47A1 but showed no detectable SLC22A6, the arachnoid marker. The same pattern held in bulk RNA sequencing of 185 meningiomas across grades I to III, with dural topics dominating in merlin-intact, immune-enriched and hypermitotic methylation subtypes alike.

Genetic evidence pointed the same way. Because both tumour suppressors and oncogenes must normally be expressed in a cell before transformation can occur, the researchers compiled the 20 most frequently mutated genes in meningiomas from the COSMIC Cancer database and measured their collective expression across the fetal and adult meningeal cell types. The dural lineage—particularly committed dura precursors and inner dura cells—showed by far the highest expression of these putative cancer drivers, a result that persisted even after removing genes commonly mutated in glioblastoma, intestinal or pancreatic cancers. The authors are careful to frame this as a hypothesis rather than a settled fact: it remains possible that tumours arising from arachnoid barrier cells later convert to a dura-like state, and previous mouse models that generated meningiomas from PTGDS-expressing cells did not distinguish arachnoid barrier from inner dura, since PTGDS is expressed in both. Still, the convergence of spatial, single-cell, bulk and genetic lines of evidence makes dural cells a serious new candidate for the meningioma cell of origin.

The clinical implications could be substantial. Higher-grade atypical and anaplastic meningiomas currently have no effective drug therapies, a failure partly attributed to decades of uncertainty about what these tumours actually are. If meningiomas are, at a transcriptional level, dural tumours, then therapeutic strategies, animal models and drug screens designed around arachnoid biology may have been aiming at the wrong target. The atlas itself—freely available through public repositories including the European Genome-Phenome Archive and GitHub—now provides the reference framework the field has lacked, charting not only the fibroblast layers but the immune, vascular and choroid plexus cells that co-develop with them. Whether dura-lineage cells can truly give rise to meningiomas will require lineage-tracing and functional experiments, but this study has, for the first time, given the question a molecular foundation—and in doing so, it has reopened a debate that medicine thought it had closed more than 150 years ago.

Subject of Research: Single-cell and spatial transcriptomic mapping of human fetal meninges development and its implications for the cellular origin of meningiomas

Article Title: Cell atlas of the developing human meninges reveals a dura-like nature of meningiomas

Article References: Vinsland, E., Marco Salas, S., Kapustová, I., Hu, L., Webb, S., Li, X., He, X., Nilsson, M., Haniffa, M., Barker, R. A., Persson, O., Raleigh, D. R., Sundström, E., Lönnerberg, P., & Linnarsson, S. (2026). Cell atlas of the developing human meninges reveals a dura-like nature of meningiomas. Nature Cell Biology. https://doi.org/10.1038/s41556-026-02074-9

Image Credits: AI Generated

DOI: 10.1038/s41556-026-02074-9

Keywords: meninges, meningioma, dura mater, arachnoid, single-cell RNA sequencing, spatial transcriptomics, fetal development, cell atlas, brain tumours, fibroblasts, tight junctions, cell of origin

The significance of the study lies partly in the sheer ubiquity of the exposure. Fungal infections are among the most frequent ailments in pregnancy, driven by hormonal and immunological changes that alter the body’s microbial balance. They are typically treated with azole antifungals, a broad family of compounds that includes both prescription drugs and, crucially, over-the-counter topical products such as creams and vaginal tablets. As Gylli Mola, a researcher and medical doctor at Rigshospitalet, points out, this is what makes the result particularly noteworthy: the treatments in question were primarily non-prescription topical preparations, which have traditionally been regarded as safe to use during pregnancy. If even these low-intensity, locally applied formulations are associated with hormonal signals in offspring, the assumption of safety may need to be re-examined with more rigorous data than currently exists.

The study rested on an unusually broad evidentiary base. The researchers analysed data from 589 Danish mother–child pairs, drawing on Denmark’s rich national registers and biobanks to compare children whose mothers had used azole antifungals during pregnancy with those who had not. Crucially, the epidemiological signal did not stand alone. The team supplemented the population data with laboratory experiments using human fetal adrenal tissue, allowing them to observe directly how azole compounds interact with the steroid-producing machinery of the gland. They also carried out studies in pregnant rats, examining both blood and adrenal tissue from the fetuses to see whether the same hormonal disruptions appeared in a controlled experimental setting. According to Monica Kam Draskau, a researcher at the DTU National Food Institute who worked on the experimental analyses, the fact that the findings in children are supported by results from both human fetal adrenal tissue and rat experiments strengthens the hypothesis that there is a genuine link with the use of azole-based antifungal medicines.

To understand why the adrenal gland matters here, it helps to consider what azoles actually do. Azole antifungals work by inhibiting enzymes in the cytochrome P450 family that fungi need to build ergosterol, an essential component of their cell membranes. The trouble is that humans rely on closely related P450 enzymes to manufacture steroid hormones, including the cortisol and other adrenal steroids that the fetus begins producing as its adrenal gland develops. A compound designed to block fungal steroid synthesis can, in principle, also interfere with human steroidogenesis, and the fetal adrenal gland is an extraordinarily active steroid-producing organ during gestation. The new findings are consistent with that mechanism: prenatal exposure to azoles appears to disrupt fetal steroidogenesis, and the disruption seems to leave traces that persist at least into early infancy.

Adrenal hormones are far from peripheral players in human physiology. They help regulate many functions in the body, including glucose metabolism, blood pressure, immune function, and growth and reproductive development. The adrenal gland also undergoes a remarkable transformation around the time of birth, known as the zona reticularis transition, when the fetal zones of the gland regress and adult-type steroid production takes over. Hormonal disturbances during this window could, in theory, ripple across multiple organ systems as a child grows. That is precisely why the Danish team is cautious but concerned: the hormone levels they measured at three months of age were still within the normal range, yet the pattern of change suggests that fetal development may have been affected in ways that standard clinical thresholds do not capture.

Professor Terje Svingen from the DTU National Food Institute, who led the work, described the persistence of the signal as striking. It is one thing, he noted, for a medicine to produce a transient hormonal blip that resolves within days; it is quite another for the use of azole-based antifungals during pregnancy to appear to affect adrenal hormone levels in children long after birth. The three-month timepoint means the differences survived the profound hormonal upheaval of delivery and the establishment of infant adrenal function. Svingen’s framing captures the careful middle ground the study occupies: the results suggest that fetal development may have been affected, but they stop well short of demonstrating harm, and the researchers are explicit that they do not know whether the differences will affect the children’s health or their ability to have children later in life.

That caution is scientifically essential. The study is observational in its human component, and it cannot directly establish that azole-based antifungal medicines cause the hormonal changes observed in children. Mothers who used antifungals may differ in other ways from those who did not, from infection severity to other medication use, and no observational design can fully exclude such confounding. Nor can the researchers conclude from this study that commonly used antifungal medicines are harmful to children. What the results do is raise a hypothesis, supported by converging lines of evidence, that now needs to be tested with dedicated studies. The authors argue that the safety of widely used antifungals during pregnancy warrants further investigation, and the triangulation of human data, human tissue experiments and animal studies gives that argument unusual weight for a finding of this kind.

The research was carried out as part of the MERLON research project and was funded by the Danish Environmental Protection Agency through the Danish Centre on Endocrine Disrupters, with additional support from the Rigshospitalet Research Council. IRSET in France was a partner in the study. That funding provenance is telling: endocrine disruption, the interference of chemicals with the body’s hormone systems, has become a major focus of European regulatory science, and medicines are increasingly scrutinised alongside industrial chemicals for their potential to perturb hormonal development. The authors declare no conflicts of interest, and the study appeared under the title ‘Prenatal antifungal exposure disrupts fetal steroidogenesis and is associated with persistent effects in children’.

For pregnant women, the immediate practical message is one of reassurance rather than alarm. Untreated fungal infections carry their own risks, and no current evidence indicates that a course of azole treatment harms a child; the measured hormone levels in the study remained within normal limits. The researchers themselves stress that they cannot conclude the medicines are harmful. The appropriate response, they suggest, is not for women to avoid needed treatment but for regulators, clinicians and researchers to generate the data needed to confirm or refute the signal. Larger cohorts, longer follow-up of exposed children, and mechanistic work clarifying which azoles, doses and exposure windows matter most would all help determine whether the hormonal differences observed at three months of age are a transient footprint or a marker of lasting developmental change.

The study also speaks to a broader lesson in pharmacology and public health: medicines assumed to be safe because they are old, familiar and available without prescription are not automatically free of subtle developmental effects. Topical preparations deliver lower systemic doses than oral drugs, but pregnancy is a period of exquisite hormonal sensitivity, and the fetal adrenal gland is one of the most hormonally active tissues in the body. The Danish findings do not overturn clinical practice, but they add an important data point to the ongoing effort to make medication use in pregnancy evidence-based rather than assumption-based. Until that evidence matures, the study stands as a carefully hedged but consequential reminder that even the most routine treatments of pregnancy deserve continued scientific scrutiny.

Subject of Research: Effects of prenatal azole antifungal exposure on fetal steroidogenesis and infant adrenal hormone levels

Article Title: New study raises questions about antifungal treatments during pregnancy

Article References: New study raises questions about antifungal treatments during pregnancy. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: azole antifungals, pregnancy, fetal development, adrenal hormones, steroidogenesis, endocrine disruption, Communications Medicine, DTU National Food Institute, Rigshospitalet, over-the-counter medicines, child health, pharmacovigilance

The research team, led by investigators at Karolinska Institutet, linked six national health and socioeconomic registers covering every live-born singleton in Sweden across a fourteen-year window. Of the 1,455,645 children included, 90,046, or 6.2 percent, were born to mothers diagnosed with an autoimmune disease before or during pregnancy. These conditions, which range from type 1 diabetes and autoimmune thyroiditis to rheumatoid arthritis, lupus and inflammatory bowel disease, arise when the immune system mistakenly attacks the body’s own tissues, sustaining chronic inflammation and producing autoantibodies that can cross the placenta.

Over a median follow-up of 15.3 years, yielding more than 22 million person-years of observation, 426 deaths occurred among children of mothers with autoimmune diseases compared with 5,728 deaths among the unexposed. After adjusting for birth year, maternal age, education, country of birth, parity, marital status, smoking in early pregnancy and pre-existing maternal cardiovascular disease and type 2 diabetes, children of exposed mothers had a 22 percent higher risk of death from any cause, corresponding to a hazard ratio of 1.22. The estimate proved stable across successive statistical models, suggesting that observable socioeconomic and health differences between the groups could not account for the association.

Beneath the overall figure lay striking heterogeneity. Maternal type 1 diabetes roughly doubled offspring mortality risk, with a hazard ratio of 1.99, and elevated risks also appeared for connective tissue diseases and autoimmune thyroiditis. In contrast, maternal skin, blood and gastrointestinal autoimmune conditions showed little or no association. The endocrine diseases carry particular biological weight because they combine immune dysregulation with metabolic disturbance, a combination known to impair placental function and fetal growth, and the study’s authors note that the type 1 diabetes findings align with earlier smaller studies that reported lasting consequences for children exposed to hyperglycemia in utero.

Perhaps the most consequential discovery concerned timing. When follow-up was divided by age, the association was strongest during infancy, with a hazard ratio of 1.21 in the first year of life, while estimates for childhood, adolescence and young adulthood were weaker and statistically imprecise. Cause-of-death analysis reinforced this developmental picture: the excess risk was driven overwhelmingly by natural causes, specifically conditions originating in the perinatal period, with a hazard ratio of 1.43, and congenital malformations and chromosomal abnormalities, at 1.29. There was no clear association with infections, cancers, circulatory or nervous system diseases, and no association whatsoever with unnatural deaths such as accidents, an outcome-based negative control that strengthens confidence in the specificity of the biological signal.

Determining whether maternal disease itself causes harm, rather than merely marking shared family vulnerabilities, is the central challenge of any observational study of this kind. The researchers deployed two complementary designs. First, they compared maternal autoimmune diseases with paternal autoimmune diseases during the same pregnancies. Because fathers share genes and household environments with their children but cannot influence fetal development through the intrauterine route, a paternal signal would suggest familial confounding. Instead, paternal autoimmune diseases showed essentially no association with offspring mortality, while the maternal association remained strong, and the maternal-to-paternal hazard ratio reached 1.40 for any autoimmune disease and 2.73 for type 1 diabetes.

Second, cousin comparisons, in which offspring of sisters discordant for autoimmune disease were contrasted while stratifying on the maternal grandmother, partially controlled for shared genetics and early-family environment. These analyses attenuated the overall association to a hazard ratio of 1.04, though the confidence interval widened considerably because far fewer informative comparisons were available. Maternal type 1 diabetes retained a substantially elevated estimate even in this restricted sample, at a hazard ratio of 2.63. Taken together, the authors argue, the family-based evidence is consistent with the hypothesis that shared familial factors alone do not fully explain the findings, leaving room for genuine intrauterine mechanisms, while acknowledging that extrauterine pathways tied to pregnancy and the postnatal period cannot be excluded.

To probe those mechanisms, the team turned to formal mediation analysis within a counterfactual framework, asking whether adverse birth outcomes carry the excess risk from maternal disease to offspring death. Preterm birth emerged as the dominant candidate, mediating an estimated 53 percent of the all-cause association and roughly three-quarters of the association with perinatal-cause deaths, though wide confidence intervals counsel caution about the precise magnitude. Small for gestational age birth mediated a smaller but notable share, about 17 percent of all-cause mortality and 24 percent of perinatal deaths, while congenital heart disease accounted for around 7.5 percent. Large for gestational age, intriguingly, mediated nothing, suggesting the effect runs through restricted growth and early delivery rather than through fetal overgrowth.

The biological logic supporting these findings is well established in developmental science. Chronic maternal inflammation, immune dysregulation and transplacental autoantibody transfer can damage placental function and disrupt fetal development, producing structural and physiological alterations that heighten vulnerability in the first weeks of life. In pregnancies complicated by type 1 diabetes, metabolic and inflammatory disturbances compound one another. Notably, the cohort was born from 2001 onward, an era in which clinical management of autoimmune disease in pregnancy improved substantially, yet excess early-life mortality persisted, indicating that suboptimal care alone is unlikely to explain the pattern. Sex-stratified analyses also hinted at greater vulnerability in boys, with a 28 percent increased risk in males versus 14 percent in females, echoing the well-documented male disadvantage in perinatal survival.

The study’s limitations temper but do not overturn its conclusions. Register data cannot capture diagnoses made exclusively in primary care, medication exposures during pregnancy or the full severity spectrum of maternal disease, and residual confounding by unmeasured behaviors or pregnancy management remains possible. Because only live births were included, any effect of maternal autoimmune disease on fetal loss would have been invisible, potentially underestimating the true impact. Some subgroup estimates rest on small numbers of deaths and must be treated as hypothesis-generating. Still, the authors emphasize that if confirmed, the findings identify pregnancy and the perinatal window as critical opportunities for intervention: optimizing maternal disease control before and during conception, with particular vigilance for endocrine conditions such as type 1 diabetes, alongside strengthened perinatal care, could reduce a measurable share of preventable early-life mortality.

Subject of Research: Association between maternal autoimmune diseases during pregnancy and offspring mortality from birth to young adulthood

Article Title: Maternal autoimmune diseases during pregnancy and mortality up to young adulthood in offspring: a register-based cohort study

Article References: Zhang, H., Janszky, I., Arkema, E. V., Möller, J., Liang, Y., Mo, X., & László, K. D. (2026). Maternal autoimmune diseases during pregnancy and mortality up to young adulthood in offspring: a register-based cohort study. eClinicalMedicine, Article 104237. https://doi.org/10.1016/j.eclinm.2026.104237

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104237

Keywords: maternal autoimmune disease, offspring mortality, type 1 diabetes, perinatal outcomes, preterm birth, congenital anomalies, Swedish national registers, cohort study, intrauterine mechanisms, epidemiology, fetal development, autoimmune thyroiditis

The study, published in the journal Metabolomics, drew on 65 mother–neonate pairs recruited between August 2014 and September 2017 from the labor and delivery unit of the University of Cincinnati Medical Center. All participants delivered full-term, single infants. At delivery, the team collected 15 milliliters of maternal venous blood and 10 milliliters of venous cord blood from each pair. Cord blood is a remarkably useful proxy for the fetal circulating environment: it is drawn within minutes of birth, and because the umbilical vein carries blood to the baby from the placenta, its chemical contents reflect the fetal metabolic state just before and during the delivery process, rather than after the profound physiological transition that follows separation from the placenta.

The analytical engine of the study was untargeted high-resolution metabolomics performed by liquid chromatography coupled to a Q-Exactive HF Orbitrap mass spectrometer. Each serum sample was extracted with acetonitrile spiked with stable isotope standards, and aliquots were run in triplicate under four complementary conditions: forward-phase hydrophilic interaction chromatography in positive electrospray ionization mode, and reverse-phase C18 chromatography in negative ionization mode. The instrument operated in full-scan mode at 120,000 resolution across a mass-to-charge range of 85 to 1,275. Across all 130 samples, the team detected 17,064 molecular features — ions characterized by their mass, retention time, and abundance. After stringent filtering for reliability, including exclusion of features with coefficients of variation at or above 30 percent and missingness exceeding 20 percent, 3,641 negative-mode and 5,244 positive-mode features entered the statistical analyses.

Quality control received careful attention. Samples were randomized into four analytical batches, with maternal and neonate samples deliberately not paired within batches to prevent technical artifacts from masquerading as biological differences. Standard reference materials from the National Institute of Standards and Technology, pooled plasma quality controls, and isotopically labeled internal standards were interspersed at the beginning, middle, and end of every batch, and the ComBat algorithm was applied to remove residual batch effects. These safeguards matter enormously in untargeted metabolomics, where the sheer dimensionality of the data — thousands of features measured in dozens of samples — creates ample opportunity for false positives if analytical drift goes uncontrolled.

The first statistical test was unsupervised. Principal component analysis of the log2-transformed feature data revealed clear separation between mothers and neonates in both ionization modes. In negative mode, the first two principal components explained 15.8 percent and 12.0 percent of the variance respectively, and the two groups formed distinct clusters with 95 percent confidence ellipses that barely touched. In positive mode the separation was present but less crisp, with the first two components explaining 16.0 percent and 9.5 percent of the variance and some overlap between groups — a pattern the authors attribute in part to the high dimensionality of the data and to a small set of outliers for whom no analytical error or batch bias could be identified. Crucially, the clustering arose despite the fact that the analytical batches mixed samples from both groups, arguing that the separation reflects genuine biology rather than laboratory artifacts.

To pin down which individual features drove this separation, the team then ran a metabolome-wide association study using a linear mixed-effects model. Each feature’s intensity was modeled as the outcome, with sample type — mother or neonate — as a fixed effect and a random intercept for each mother–neonate pair, thereby exploiting the paired design to control for dyad-level factors. The models were adjusted for five pre-specified covariates: maternal age, smoking status during pregnancy, cesarean delivery, neonatal sex, and number of prior pregnancies. False discovery was controlled with the Benjamini–Hochberg procedure at a permissive 20 percent threshold, a choice the authors justify by the exploratory nature of the analysis and the modest sample size relative to the number of correlated features. The result was striking: 3,720 features — 41.9 percent of those tested — differed significantly between mothers and neonates. In negative mode, 48.5 percent of features were significant, with the majority higher in neonates; in positive mode, 37.3 percent were significant, and a remarkable 85.4 percent of those were higher in the babies.

The pathway-level analysis is where the study delivers its most interesting insight. The significant features were mapped using the mummichog algorithm against the Homo sapiens MFN pathway library, with pathway significance assessed by permutation testing across 10,000 iterations. Across all significant features, 16 unique pathways were implicated, spanning five major classes of metabolism: amino acids and nucleotides, vitamins, lipids and fatty acids, energy metabolism, and a residual category. Among the amino acid and nucleotide pathways, the enriched set included the degradation of the branched-chain amino acids valine, leucine, and isoleucine, along with tyrosine, tryptophan, lysine, beta-alanine, arginine and proline, and glycine–serine–alanine–threonine metabolism. Energy pathways including propanoate and butanoate metabolism, vitamin pathways for D3, B9, and B3, de novo fatty acid synthesis, and the urea cycle also came out significant.

The asymmetry between the two generations is the headline finding. When the team restricted the pathway analysis to features that were significantly higher in mothers alone, seven pathways emerged as enriched — prominently including three lipid-related pathways: glycerophospholipid metabolism, fatty acid activation, and de novo fatty acid biosynthesis, alongside glycosphingolipid metabolism, butanoate metabolism, and two amino acid pathways. These lipid signals are consistent with well-documented physiological adaptations of pregnancy, in which the mother ramps up glucose production and develops insulin resistance to keep a steady fuel supply flowing to the fetus, while mobilizing and synthesizing fatty acids for fetal tissue construction. But when the analysis was restricted to features higher in neonates, no pathway reached statistical significance at all. The neonatal metabolic difference, in other words, is not concentrated in any single biochemical route; it is distributed diffusely across the global metabolic profile — a pattern the authors suggest is consistent with the rapid, system-wide metabolic reprogramming the newborn must execute at birth, when the continuous placental glucose supply ends and independent energy regulation begins.

Study co-author Katherine E. Manz of the University of Michigan and colleagues frame the work as a baseline map rather than a clinical verdict. The evidence supports the conclusion that maternal metabolomes are not adequate proxies for fetal metabolomes — a finding with practical consequences. Epidemiologists studying how environmental chemicals, nutrition, and maternal health shape fetal development frequently measure metabolites in maternal blood and infer fetal exposures; this study suggests those inferences carry real uncertainty. The team’s related work in the same cohort reinforces the point: in studies of polycyclic aromatic hydrocarbons, 43 of 59 exposure-associated metabolic pathways were distinct between mothers and neonates, and endocrine-disrupting chemicals likewise produced divergent metabolic signatures in the two generations, with only partial overlap.

The authors are candid about limitations. The cohort of 65 pairs is modest, limiting statistical power, and the 20 percent false discovery threshold, while defensible for exploratory work, means some reported features may be spurious. Unmeasured confounders — maternal diet in particular, along with unknown environmental exposures — could explain some of the dyad-level variation, and because fetal blood cannot be sampled in utero, the study cannot determine when during gestation the maternal–fetal metabolic divergence first appears. What it can establish, and does, is that at the moment of birth, before any postnatal adaptation begins, mother and baby are already biochemically distinct in measurable, pathway-informative ways. As untargeted metabolomics becomes cheaper and more widespread, the practice of treating maternal blood as a window onto fetal chemistry will need recalibration — and the distinct metabolic logic of the newborn, still largely unorganized into discrete pathways at birth, represents a frontier for understanding the critical transition from fetal to independent life.

Subject of Research: Comparative untargeted metabolomics of paired maternal and umbilical cord blood samples at delivery to determine whether maternal metabolic profiles can proxy fetal metabolic profiles.

Article Title: Comparative metabolomics of paired maternal–cord samples identifies pathway-level divergence

Article References: Van Winckel, A., Gupta, M., Klein, R., Puvvula, J., Braun, J. M., Pennell, K. D., DeFranco, E. A., Ho, S.-M., Leung, Y.-K., Vuong, A. M., Percy, Z., Bhashyam, P., Lee, R., Jones, D. P., Tran, V., Kim, D. V., Huang, S., Chen, A., & Manz, K. E. (2026). Comparative metabolomics of paired maternal–cord samples identifies pathway-level divergence. Metabolomics, 22(5), Article 157. https://doi.org/10.1007/s11306-026-02528-z

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02528-z

Keywords: metabolomics, pregnancy, umbilical cord blood, neonate, maternal metabolism, mass spectrometry, metabolic pathways, fetal development, lipid metabolism, principal component analysis, MWAS, perinatal health

The research team, led by Loren K. Barcenas of the Department of Health Behavior and senior author Leah Frerichs, conducted a systematic review of published systematic reviews, meta-analyses, and scoping reviews, following the PRISMA reporting guidelines that govern how evidence syntheses are identified, screened, and reported. The investigators searched three major biomedical databases, PubMed, Embase, and the Cumulative Index in Nursing and Allied Health Literature, for reviews published since 2014 that examined opioid impacts on pediatric populations. Two reviewers independently screened candidate articles and evaluated the methodological quality of each included review using the 11-item Joanna Briggs Institute criteria checklist, a standardized tool for judging how rigorously a review was conducted. From that process, twenty studies met the inclusion criteria and formed the evidentiary backbone of the umbrella review.

One sober methodological finding deserves attention before the substance: the average quality score of the included reviews was just 5.75 out of 11. That number signals to readers that while the collective evidence is broad, much of it rests on reviews with methodological limitations, whether in their search strategies, their assessment of individual studies, or their handling of bias. The authors are transparent about this constraint, and it frames the review’s conclusions as a map of what is known, and what is known less well, rather than a set of definitive effect estimates. For a field in which research funding and policy attention have historically flowed toward adult populations, that uneven evidence base is itself part of the story.

What the twenty reviews did document falls into four major outcome categories: physical health, neurodevelopment, psychosocial outcomes, and caregiving disruptions. The physical health effects are most visible in newborns. Infants exposed to opioids in the womb can develop neonatal abstinence syndrome, increasingly called neonatal opioid withdrawal syndrome, a constellation of withdrawal symptoms that can include irritability, feeding difficulties, tremors, and the need for extended hospitalization and pharmacologic treatment. These conditions have become a barometer of the crisis’s reach into delivery wards, and the umbrella review confirms that infants with prenatal opioid exposure are the most extensively studied pediatric group in the literature, with a substantial body of work documenting their immediate clinical course and early health trajectories.

Beyond the neonatal period, the evidence turns to neurodevelopment. Reviews synthesized in the analysis examined whether prenatal opioid exposure is associated with differences in cognitive performance, language development, motor skills, attention, and behavior as children grow. Attention deficit hyperactivity disorder emerges repeatedly in this literature as an outcome of concern, alongside broader questions about school readiness and executive function. The review’s authors are careful to note that isolating the effect of opioids from the confounding factors that travel with them, including prenatal exposure to other substances, maternal stress, poverty, and disrupted caregiving, remains a persistent methodological challenge. Still, the convergence of findings across multiple independent reviews supports the conclusion that opioid exposure can leave developmental traces that persist well past infancy.

The third and fourth domains extend the analysis beyond the exposed child to the family system. Psychosocial outcomes documented in the reviews include elevated risks for mental health difficulties, challenges with emotional regulation, and social adversity among children affected by their own exposure or by parental opioid misuse. Caregiving disruptions, meanwhile, capture a quieter but potentially profound harm: children whose parents struggle with opioid use disorder may experience instability in daily routines, foster care placement, kinship care arrangements, or the loss of a parent to overdose or incarceration. The umbrella review emphasizes that these indirect effects, transmitted through caregivers rather than through pharmacologic exposure, have received far less research attention than prenatal exposure, even though they affect a population that is at least as large.

That gap in the evidence is one of the review’s central messages. Effects were most extensively documented in infants with prenatal exposure, while research on parental opioid misuse affecting children, and on opioid misuse among adolescents and emerging adults themselves, remains comparatively thin. This is a striking asymmetry given that adolescents and young adults ages roughly 15 to 24 are among the groups at rising risk of initiating opioid misuse and developing opioid use disorder. The review explicitly flags adolescents and emerging adults as priority populations for future investigation, arguing that without better evidence, interventions and policies for these age groups will rest on extrapolation rather than on solid data.

Perhaps the most conceptually important finding concerns moderation. Across the synthesized literature, environmental factors, particularly socioeconomic status and the quality of caregiving, emerged as significant moderators of outcomes. In plain terms, the same pharmacologic exposure can lead to markedly different developmental trajectories depending on the resources, stability, and responsiveness of the child’s environment. This reframes opioid exposure not as biological destiny but as one risk operating within a web of protective and aggravating factors. It also offers a measure of hope: environments can be changed. Stable housing, responsive parenting support, early educational enrichment, and economic assistance are all modifiable, and the review’s findings suggest they may meaningfully alter the long-term outlook for affected children.

The authors translate this into a call for comprehensive early intervention that spans healthcare, education, and social services rather than treating opioid-related pediatric harm as a purely medical problem. For infants with neonatal opioid withdrawal syndrome, that means continued investment in evidence-based treatment and developmental follow-up. For young children affected by parental substance use, it means supporting caregivers through medications for opioid use disorder and family-centered services that keep families together when safe and possible. For adolescents, it means prevention and treatment systems designed for their developmental stage. The interconnected nature of the harms documented in the review, the authors argue, demands a correspondingly interconnected response, one that a single clinic or program cannot deliver alone.

Published as an open-access article with a permanent DOI, the review arrives at a moment when the crisis continues to evolve, with synthetic opioids reshaping exposure patterns in ways the included literature only partially captures. Its funding came from the William T. Grant Foundation, whose support runs through 2028, reflecting a funder focus on youth wellbeing. As a synthesis of syntheses, the paper does not offer a single headline statistic, and its authors would be the first to acknowledge that the quality of the underlying evidence averages barely above the midpoint of the assessment scale. What it does offer is a structured, honest account of how opioid misuse reverberates from the prenatal period through emerging adulthood, where the evidence is strong, where it is fragile, and where the next decade of research must go if children affected by the crisis are to receive interventions grounded in evidence rather than assumption.

Subject of Research: The effects of opioid misuse on fetal development, infants, children, adolescents, and emerging adults

Article Title: The impact of opioid misuse on fetal and pediatric populations: a systematic umbrella review

Article References: Barcenas, L. K., Kaz, L., Frerichs, L., & Hassmiller-Lich, K. (2026). The impact of opioid misuse on fetal and pediatric populations: a systematic umbrella review. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00715-w

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00715-w

Keywords: opioid epidemic, pediatrics, fetal development, neonatal abstinence syndrome, neonatal opioid withdrawal syndrome, neurodevelopment, mental health, parental opioid misuse, caregiving disruption, umbrella review, early intervention, adolescent health

The placenta is far more than a passive conduit for nutrients and oxygen. It is a highly regulated immunological interface, an organ that must tolerate a genetically distinct fetus while still defending both mother and child from infection. Resident macrophages, the immune cells that patrol placental tissue, are central to this balancing act. In their resting, anti-inflammatory M2 state, these cells promote immune tolerance, tissue remodeling, and healthy vascular development. When they shift into the pro-inflammatory M1 state, they mount antimicrobial responses but also unleash cytokines that can damage the very tissue they inhabit. A healthy pregnancy depends on keeping this polarity in check, and the new research shows that nanoplastic particles can tip the scales decisively toward inflammation.

To probe the risk, the team built a two-tier experimental strategy that combined animal and human models. In vivo, pregnant mice were exposed to polystyrene nanoplastics during gestation, allowing the researchers to examine placental toxicity in a living system where maternal circulation, fetal development, and immune signaling all interact. In parallel, the investigators developed an in vitro co-culture system pairing HTR8/SVneo cells, a widely used model of human extravillous trophoblasts, with macrophages derived from THP-1 human monocytic leukemia cells treated with phorbol ester to induce differentiation. This dual design let the researchers observe the consequences of exposure in intact placentas while dissecting the cellular mechanisms at single-cell-type resolution.

The first major finding emerged from RNA sequencing of placentas harvested from exposed mice. Transcriptomic analysis revealed significant enrichment of inflammatory response pathways, including the gene ontology term GO:0006954 and multiple associated KEGG signaling pathways. In plain terms, the exposed placentas looked inflamed at the level of their gene expression. Crucially, the researchers then confirmed that this inflammatory signature was accompanied by a measurable shift in macrophage polarization: the population of immune cells within placental tissue had moved toward the M1, pro-inflammatory phenotype, at the expense of the M2, anti-inflammatory state that normally predominates in a healthy pregnancy.

From the sequencing data, the team zeroed in on three differentially expressed genes linked to inflammation: ARG1, which encodes arginase 1, a hallmark enzyme of the M2 program; CCR5, a chemokine receptor involved in immune cell trafficking and inflammatory signaling; and IL1R2, a decoy receptor for the inflammatory cytokine interleukin-1. All three were carried forward for validation in the human cell system using RT-qPCR, a technique that quantifies gene expression with high sensitivity. In PMA-treated THP-1 macrophages exposed to the nanoparticles, ARG1 and CCR5 were consistently downregulated, while IL1R2 was upregulated. Immunohistochemistry on placental tissue corroborated the changes at the protein level.

Among the three candidate markers, only one behaved identically across every layer of evidence. ARG1 showed consistent downregulation at both the transcriptional level, detected independently by RNA sequencing and RT-qPCR, and the translational level, detected by immunohistochemistry. CCR5 and IL1R2, by contrast, did not maintain the same coherent pattern across all assays. This convergence convinced the researchers that ARG1 stands out as a robust and reliable indicator of nanoplastic-induced placental toxicity, a biomarker candidate that could prove valuable both for future mechanistic studies and, potentially, for monitoring real-world exposure effects.

The functional implications go deeper than correlation. Because arginase 1 is a defining effector molecule of the M2 program, its suppression effectively disarms the anti-inflammatory arm of placental macrophages. In the co-culture experiments, the researchers demonstrated that nanoplastic exposure suppressed the M2 anti-inflammatory phenotype while promoting the M1 pro-inflammatory phenotype, and that this polarization shift was driven by the inhibition of ARG1 expression. In other words, the particles do not simply provoke a generic inflammatory reaction; they reprogram immune cell identity by switching off a master regulator of the tolerance-promoting state. The macrophages themselves become agents of placental injury, releasing inflammatory signals in tissue that depends on calm for its function.

This mechanism helps explain how an environmental exposure could translate into developmental risk. An inflamed placenta is an inefficient placenta. Pro-inflammatory macrophage polarization has been implicated in a range of pregnancy complications, including preeclampsia, fetal growth restriction, and abnormal trophoblast invasion, and prior work by the same group linked nanoplastic exposure to ferroptosis, an iron-dependent form of cell death, in placental tissue through epigenetic mechanisms. The new findings add an immunological layer to that picture: even before cells die, the microenvironment around them is being pushed into a state that undermines nutrient exchange, vascular remodeling, and maternal-fetal immune tolerance, all of which are essential for normal fetal growth.

The study also arrives amid a rapidly expanding body of evidence that plastic particles penetrate the most protected compartments of the human body. Researchers have quantified microplastics in human placental specimens using pyrolysis gas chromatography mass spectrometry, detected them in maternal blood and umbilical vein blood, and traced their accumulation from placenta to fetal organs in animal models. Particle size matters as well: smaller nanoplastics cross biological barriers more readily than microplastics, and previous studies have shown that different particle sizes can differentially regulate pro-inflammatory macrophage polarization. What distinguishes the new work is that it moves beyond documenting the presence of these particles and identifies a specific molecular lever, ARG1, through which they exert their effect on a critical organ.

The researchers emphasize that their findings highlight a new risk factor for fetal development, one that arises from the collision between global plastic pollution and the immunological choreography of pregnancy. While the experiments were conducted in mouse models and human cell lines, the conserved biology of macrophage polarization and placental immune regulation suggests the mechanism is plausibly relevant to human pregnancies, particularly given the documented presence of plastics in human placentas. As nanoplastic contamination of air, food, and water continues to rise, the study underscores that the most vulnerable window of human development may be quietly exposed to particles capable of reprogramming the immune cells charged with protecting it. Identifying ARG1 as a consistent molecular signature of that exposure provides researchers with a concrete target for biomarkers, interventions, and, ultimately, a better understanding of how the modern material world shapes the earliest chapters of life.

Subject of Research: Effects of gestational polystyrene nanoplastic exposure on placental function and macrophage polarization

Article Title: Gestational polystyrene nanoplastic exposure impairs placental function via ARG1-associated macrophage polarization imbalance

Article References: Yujiao, C., Yifan, L., Shanshan, L., Wei, W., Meng, Z., & Yousheng, Y. (2026). Gestational polystyrene nanoplastic exposure impairs placental function via ARG1-associated macrophage polarization imbalance. Journal of Nanoparticle Research, 28(9), Article 242. https://doi.org/10.1007/s11051-026-06764-1

Image Credits: AI Generated

DOI: 10.1007/s11051-026-06764-1

Keywords: polystyrene nanoplastics, placental toxicity, macrophage polarization, ARG1, pregnancy, placenta, inflammation, fetal development, nanotoxicology, trophpoblast, HTR8/SVneo, immune tolerance

The research, led by Audra R. Barnes-Lanier and John C. Chappell at Virginia Tech’s Fralin Biomedical Research Institute, provides the first detailed look at how these soluble receptor variants behave in the developing placenta of both mice and humans. The team documented progressively increasing pericyte coverage of fetoplacental capillaries across gestation, confirmed that placental pericytes display the same phenotypic diversity seen in the brain, heart, and lungs, and then demonstrated that soluble PDGFRβ isoforms are produced at both the RNA and protein levels throughout pregnancy. Most intriguingly, their functional experiments suggest these soluble fragments can modulate the very signaling pathway that recruits pericytes to nascent blood vessels in the first place.

Pericytes are specialized mural cells that wrap around capillaries, reinforcing vessel integrity and coordinating vascular maturation through intimate communication with endothelial cells. The primary chemical conversation between these two cell types runs through platelet-derived growth factor-BB, or PDGF-BB, which endothelial cells display on their surfaces to attract PDGFRβ-bearing pericytes. Decades of genetic work have shown that this pathway must be calibrated with extraordinary precision. Too little PDGF-BB signaling and pericytes abandon the vessel wall, leaving fragile, leaky, hemorrhage-prone capillaries; in mice, loss of PDGF-B or PDGFRβ produces placental abnormalities among a constellation of developmental defects. Too much signaling, on the other hand, drives pericyte hyperproliferation, vascular malformations, and fibrosis, as seen in patients carrying activating PDGFRB mutations.

Soluble receptor isoforms have emerged as one way biology walks this tightrope. Across the receptor tyrosine kinase family, truncated receptor variants generated by alternative mRNA splicing or proteolytic cleavage can act as decoys, sponging up ligand or interfering with full-length receptor activity. The most celebrated example is soluble Flt-1, or sFlt-1, which restrains VEGF-A signaling during vascular sprouting and, when misregulated in the placenta, becomes a central driver of preeclampsia. Until recently, however, soluble PDGFRβ was largely viewed as a degradation product, a biomarker of pericyte damage detected in the aging and diseased brain rather than a molecule with a job of its own. That view began to shift when the Chappell laboratory and collaborators showed that alternatively spliced sPDGFRβ transcripts and proteins are produced under entirely normal developmental conditions.

In the new work, the team turned to the placenta to ask whether these variants might matter during pregnancy. Examining mouse placentas at embryonic days 9.5, 14.5, and 18.5, they found that NG2-positive pericytes appear alongside the earliest vasculogenic structures and progressively invest the expanding capillary network, matching the pace of endothelial growth. Transcriptional analysis confirmed rising expression of pericyte genes including Cspg4, Acta2, and full-length Pdgfrβ across gestation, alongside coordinated changes in the Vegfa, Flt-1, and Pdgfb pathways. Western blotting revealed parallel increases in both the full-length receptor, at roughly 160 kilodaltons, and truncated soluble isoforms. Human placenta samples from uncomplicated full-term pregnancies told the same story, with full-length PDGFRβ and a shorter, soluble variant present in every quadrant examined, though with notable regional heterogeneity across the organ.

To dissect how sPDGFRβ is regulated and what it does, the researchers exploited a murine trophoblast and embryonic stem cell differentiation model, or TESC model, that recapitulates key features of early placental vascular development. As these stem cells differentiated, they formed primitive vascular networks containing fluorescently labeled endothelial cells and pericyte progenitors, while also generating trophoblast lineage cells marked by cytokeratins and the tight junction protein ZO-1, mirroring the cellular constituents of the developing placenta. Within this system, soluble PDGFRβ proteins appeared and accumulated alongside full-length receptor during vessel formation, accompanied by transcripts encoding intron-4 and intron-10 truncation variants previously characterized in the healthy brain.

The regulation experiments yielded two unexpected findings. First, blocking the metalloprotease ADAM10, long implicated in shedding soluble PDGFRβ from damaged pericytes, had no effect on soluble receptor levels during early vessel formation, and instead increased full-length receptor abundance, suggesting that in the developmental context, alternative mRNA splicing rather than proteolytic cleavage is the dominant source. Second, exogenous growth factors failed to boost sPDGFRβ production; adding VEGF-A or PDGF-BB to the cultures actually lowered soluble isoform levels slightly, while PDGF-BB significantly reduced full-length receptor, consistent with ligand-induced receptor internalization and degradation. Hypoxia, however, proved to be a powerful stimulus, driving a robust and sustained increase in soluble PDGFRβ protein after just 12 hours at 3 percent oxygen, and again at 48 hours, while full-length receptor remained unchanged.

That hypoxic sensitivity may be the key to the whole story, because low oxygen tension is a defining feature of early placentation and a hallmark of placental insufficiency. To test whether elevated sPDGFRβ could actually influence PDGF-BB signaling, the team added a soluble receptor mimetic, a peptide spanning the PDGF-BB ligand-binding domain, to their developing vascular networks. As expected, excess PDGF-BB alone reduced full-length PDGFRβ levels while increasing phosphorylation of the receptor at a key regulatory tyrosine residue. But when the mimetic was co-administered, both effects were attenuated, pulling receptor abundance and phosphorylation back toward baseline. The result supports a model in which soluble PDGFRβ acts as a negative feedback modulator, buffering PDGF-BB signaling against overshoot, particularly when hypoxia threatens to destabilize the system.

The implications reach well beyond basic vascular biology. Pericyte dysfunction at the maternal-fetal interface is increasingly implicated in preeclampsia, fetal growth restriction, and the abnormal, poorly perfused vessels that characterize placental insufficiency, conditions that also elevate sFlt-1 and disrupt maternal cardiovascular health. If sPDGFRβ proves to be similarly misregulated in pathological pregnancies, it could serve as both a biomarker for stratifying at-risk patients and a therapeutic target for stabilizing fetoplacental vascular maturation. The authors also point to broader questions about why pericytes diversify into contractile and non-contractile subtypes across organs, and how RNA-binding proteins and splicing factors orchestrate soluble receptor production. Follow-on studies are already planned to validate sPDGFRβ transcript and protein structures, screen disease databases for associations with placental dysfunction, and determine whether the same oxygen-sensitive feedback loop protects, or fails to protect, the fragile vasculature of pregnancies under stress.

The placenta offers an unusually instructive setting in which to study soluble receptor biology because its oxygen environment changes dramatically over the course of gestation. Early placentation occurs under relatively low oxygen tension, a physiological state that protects the developing embryo from oxidative damage while the fetoplacental circulation is still being assembled. The observation that hypoxia robustly increased soluble PDGFRβ production in the TESC model, without altering full-length receptor abundance, suggests that the placenta may naturally encounter conditions that favor soluble isoform generation precisely when vascular remodeling is most active. This oxygen-sensitive behavior distinguishes sPDGFRβ from many other signaling modulators whose expression is driven primarily by ligand availability.

The distinction between alternatively spliced and proteolytically shed soluble receptor variants carries practical consequences for future research. Shed receptor fragments released from damaged pericytes have historically been interpreted as passive markers of injury, whereas splice-derived isoforms represent deliberate gene products that can be regulated independently of cell death or membrane cleavage. The finding that ADAM10 inhibition did not reduce soluble receptor levels during early vessel formation, and instead raised full-length receptor abundance, implies that the developmental placenta relies on transcriptional mechanisms rather than ectodomain shedding. This matters therapeutically, because strategies targeting metalloprotease activity would be unlikely to influence a splicing-derived soluble pool, while interventions aimed at splicing factors or RNA-binding proteins might.

The TESC differentiation model itself deserves attention as a methodological advance. Placental tissue is difficult to obtain and study experimentally, particularly at early developmental stages, and animal models do not fully capture human trophoblast biology. A system in which trophoblast lineage cells, endothelial cells, and pericyte progenitors arise together and assemble vascular-like networks provides a tractable platform for testing how individual signaling components behave in a placental context. The demonstration that soluble PDGFRβ isoforms appear in this model at both transcript and protein levels, matching what is seen in native mouse and human tissue, strengthens confidence that the model reflects genuine developmental regulation rather than an artifact of cell culture.

Several questions remain open before these findings can be translated. The functional experiments relied on a mimetic peptide spanning the ligand-binding domain, so it is not yet certain that endogenously produced soluble isoforms exert identical effects in vivo. The precise stoichiometry between soluble receptor, PDGF-BB ligand, and membrane-bound PDGFRβ that produces meaningful modulation of signaling has not been defined. Whether soluble PDGFRβ sequesters ligand directly, competes for receptor binding, or acts through some other mechanism also remains to be resolved. Answering these questions will require genetic models in which soluble isoform production can be selectively manipulated, allowing investigators to separate the contributions of splicing-derived variants from the full-length receptor they appear to regulate.

Subject of Research: Regulation of PDGF-BB signaling in placental pericytes by soluble PDGFRβ isoforms during fetoplacental vascular development

Article Title: Regulation of PDGF-BB signaling in placental pericytes by soluble PDGFRβ isoforms: implications for fetoplacental vascular development

Article References: Barnes-Lanier, A. R., Duggan, E. C., Dunkenberger, R. A., Lessard, C. V., Cosma, C. C., Steele, C. R., Taylor, S. V., Darden, J. A., Whitham, M. D., Durica, A. R., & Chappell, J. C. (2026). Regulation of PDGF-BB signaling in placental pericytes by soluble PDGFRβ isoforms: implications for fetoplacental vascular development. Angiogenesis, 29(4), Article 67. https://doi.org/10.1007/s10456-026-10091-3

Image Credits: AI Generated

DOI: 10.1007/s10456-026-10091-3

Keywords: placenta, pericytes, PDGF-BB, PDGFRβ, soluble receptor, angiogenesis, fetal development, hypoxia, endothelial cells, preeclampsia, vascular development, alternative splicing